Shots:

• Onconova to receive $25.55M as clinical- regulatory and commercialization milestones and royalties on sales of Rigosertib. Knight therapeutics to receive exclusive rights to commercialize Rigosertib in Canada
• If approved- Rigosertib would meet the unmet medical need of the patients suffering from myelodysplastic syndromes and is currently being evaluated in P-III INSPIRE study assessing Rigosertib (IV) + BSC vs Physician's Choice + BSC in patients in a ratio 2:1 with high-risk MDS who had progressed on- failed to respond to- or relapsed on prior treatment with hypomethylating agent
• Rigosertib is a first-in-class Ras mimetic molecule that blocks the activation of Ras effector protein- currently being developed for with HR-MDS with the potential to be developed for other solid and liquid tumors with Ras pathway activation

Click here to­ read full press release/ article | Ref: Ocnonova  | Image: Ocnonova